Your session is about to expire
← Back to Search
Enriched Hematopoietic Stem Cell Infusion for Kidney Failure
Study Summary
This trial will test a new cell therapy to see if it is safe and effective in people who have had a kidney transplant from a living donor.
- Kidney Failure
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this investigational study accept individuals aged 25 and over?
"The eligibility requirements stipulate that prospective participants of this clinical trial must be between 18 to 65 years old. For patients outside these age brackets, there are 6 trials designed for those under 18 and 171 for seniors above 65."
Are there any specific requirements for enrolment in this medical research?
"To be eligible for this trial, applicants should have kidney failure and must fall within the age bracket of 18 to 65 years old. The current recruitment quota is set at 60 people."
What safety measures are in place to protect participants of Enriched Hematopoietic Stem Cell Infusions?
"Our team at Power rated the safety of Enriched Hematopoietic Stem Cell Infusion as a 2, due to the lack of efficacy-supporting data from this Phase 2 trial."
Is enrollment for this trial currently open?
"Clinicaltrials.gov shows that this clinical trial is not actively enrolling patients at the moment, despite having been initially posted on March 1st 2008 and recently updated on July 15th 2022. However, there are 177 other trials currently accepting participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger